35 / 66
Hyperprogressive
disease is a new pattern of progression in
cancer patients treated by anti-PD-1/PD-L1
Característica
Todos (n=131)
No-HPD (n=119)
HPD (n=12)
p
value
(Wilconxon test)
Leucocitos
7.1
7.1
7.9
0.45
Neutrófilos
5.1
5.1
5
0.69
PCR
21.1
21.1
21.7
0.97
Fibrinógeno
4.8
4.9
4.7
0.43
LDH
204
198
248
0.097
Albúmina
36
36
34.5
0.23
Edad
55
55
65
0.007
Vol. tumoral, mm
78
76
91
0.64
Champiat, Clinical Cancer Research 2016